{"id":"NCT01994746","sponsor":"Eli Lilly and Company","briefTitle":"Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults","officialTitle":"Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2015-01","completion":"2015-01","firstPosted":"2013-11-26","resultsPosted":"2016-10-10","lastUpdate":"2019-09-23"},"enrollment":77,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"Nasal Glucagon","otherNames":["AMG504-1","LY900018"]},{"type":"DRUG","name":"Intramuscular Glucagon","otherNames":["GlucaGen HypoKit"]}],"arms":[{"label":"Nasal Glucagon","type":"EXPERIMENTAL"},{"label":"Intramuscular Glucagon","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available glucagon given by intramuscular injection.","primaryOutcome":{"measure":"Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir","timeFrame":"Within 30 minutes after receiving glucagon at both dosing visits (glucose was measured at pre-dose; 5, 10, 15, 20, 25, and 30 minutes following glucagon administration)","effectByArm":[{"arm":"Nasal Glucagon (NG)","deltaMin":98.7,"sd":null},{"arm":"Intramuscular (IM) Glucagon","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":["26681725","38444629"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":77},"commonTop":["Nausea","Headache","Vomiting","Fatigue","Nasal discomfort"]}}